AA
ESPR

Apriem Advisors’s Esperion Therapeutics ESPR Stock Holding History

Apriem Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-640
Closed -$52K – 540
2015
Q2 		$52K Buy
640
+265
+71% +$25.9K 0.02% 209
2015
Q1 		$35K Buy
+375
New +$24.2K 0.01% 242

Other funds holding ESPR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Apriem Advisors's ESPR Position: Q3 2015 in Review

Apriem Advisors sold out of Esperion Therapeutics (ESPR) in Q3 2015, closing a stake of 640 shares — an estimated $52K sold.

Apriem Advisors first reported a position in ESPR in Q1 2015 and held it in 2 quarters. The position peaked at $52K in Q2 2015. 121 funds tracked by Wall St. Rank hold ESPR as of Q3 2015.

  • Apriem Advisors reported no remaining Esperion Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Apriem Advisors sold 640 Esperion Therapeutics shares in Q3 2015, an estimated $52K.
  • Apriem Advisors first reported a position in Esperion Therapeutics in Q1 2015 and held it in 2 quarters.
  • Apriem Advisors's Esperion Therapeutics position peaked at $52K in Q2 2015.
  • 121 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2015.

Based on Apriem Advisors's 13F filing for Q3 2015, filed 13 Nov 2015.